Skip to main content
Back to Qiming Venture Partners

Qiming Venture Partners's Pharmaceutical Portfolio

Browse 20 Pharmaceutical companies funded by Qiming Venture Partners. See funding amounts, founder contacts, and investment details.

Pharmaceutical Companies
20
Total Funding in Pharmaceutical
$1.7B

Pharmaceutical Portfolio Companies (20)

Export
BiotechnologyPharmaceutical

Aureka Biotechnologies is a pioneering biotech firm dedicated to democratizing the pharmaceutical sector in order to conquer sickness.

Laguna Hills, United States
April 2026
$23.4M
Series A

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical

AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases.

Foster City, United States
September 2025
$63.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife SciencePharmaceutical

Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.

Seattle, United States
August 2024
$144.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyGeneticsPharmaceuticalTherapeutics

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

South San Francisco, United States
January 2024
$24.0M
Series A

Founder Contacts

19,000+ verified contacts

MedicalPharmaceuticalTherapeutics

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.

Natick, United States
March 2023
$50.0M
Series B

Founder Contacts

19,000+ verified contacts

MedicalPharmaceuticalTherapeutics

Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection and wound repair.

Jiading, China
February 2026
$14.6M
Series C

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiopharmaBiotechnologyGeneticsNanotechnologyPharmaceuticalTherapeutics

BreezeBio is a biotechnology business that creates genetic therapies using precision, non-viral delivery across clinically important tissues

Brisbane, United States
February 2026
$60.0M
Series B

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyPharmaceutical

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.

Minhang, China
January 2026
Series C

Founder Contacts

19,000+ verified contacts

Health CarePharmaceuticalProduct Research

OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.

Shanghai, China
January 2026
$70.0M
Series C

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyMedicalPharmaceutical

Zenitar is a biomedical technology company engaged in innovative drug research and industrialization processes.

Chengdu, China
January 2026
$86.0M
Series C

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareMedicalPharmaceuticalProduct Research

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

South San Francisco, United States
December 2025
$747.5M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyManufacturingPharmaceutical

Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases.

Suzhou, China
December 2025
$10.0M
Seed

Founder Contacts

19,000+ verified contacts

BiotechnologyLife SciencePharmaceutical

ChemLex is a chemical synthesis CRO that was founded by Magera Technology.

Shanghai, China
December 2025
$45.0M
Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalOncologyPharmaceuticalTherapeutics

Vybio is a high-tech enterprise focusing on innovative drug research and development.

Hangzhou, China
November 2025
$14.1M
Series B

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyPharmaceutical

Brise Pharma operates in the scientific research and technical service industry.

Shanghai, China
November 2025
$28.1M
Series A

Founder Contacts

19,000+ verified contacts

Health CareMedicalPharmaceutical

Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration.

Toronto, Canada
September 2025
$754K
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CarePharmaceutical

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

Beijing, China
August 2025
$12.7M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyMedicalPharmaceuticalProduct ResearchTherapeutics

Minghui Pharmaceutical is a biopharmaceutical business that specializes in immunology and oncology medicines for unmet needs.

Shanghai, China
August 2025
$131.0M
Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalPharmaceutical

LongBio Pharma is a biotech company that treats patients with an emphasis on complement and allergy diseases.

Pudong, China
May 2025
$28.9M
Series C

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyHealth CarePharmaceutical

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

Cambridge, United States
March 2025
$123.0M
Series E

Founder Contacts

19,000+ verified contacts

Explore Qiming Venture Partners's Full Portfolio

View all companies funded by Qiming Venture Partners across every industry and funding stage.

View Full Qiming Venture Partners Portfolio